- Home
- LRE vs GOVX Comparison
LRE vs GOVX Comparison
Compare LRE & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRE
- GOVX
- Stock Information
- Founded
- LRE 2001
- GOVX 2001
- Country
- LRE Japan
- GOVX United States
- Employees
- LRE N/A
- GOVX N/A
- Industry
- LRE
- GOVX Biotechnology: Pharmaceutical Preparations
- Sector
- LRE
- GOVX Health Care
- Exchange
- LRE Nasdaq
- GOVX Nasdaq
- Market Cap
- LRE 17.6M
- GOVX 15.5M
- IPO Year
- LRE 2023
- GOVX N/A
- Fundamental
- Price
- LRE $1.80
- GOVX $0.49
- Analyst Decision
- LRE
- GOVX Strong Buy
- Analyst Count
- LRE 0
- GOVX 5
- Target Price
- LRE N/A
- GOVX $12.40
- AVG Volume (30 Days)
- LRE 15.3K
- GOVX 2.4M
- Earning Date
- LRE 01-01-0001
- GOVX 08-05-2025
- Dividend Yield
- LRE N/A
- GOVX N/A
- EPS Growth
- LRE N/A
- GOVX N/A
- EPS
- LRE 0.29
- GOVX N/A
- Revenue
- LRE $117,804,154.00
- GOVX $5,591,576.00
- Revenue This Year
- LRE N/A
- GOVX N/A
- Revenue Next Year
- LRE N/A
- GOVX N/A
- P/E Ratio
- LRE $6.19
- GOVX N/A
- Revenue Growth
- LRE 8.82
- GOVX N/A
- 52 Week Low
- LRE $1.10
- GOVX $0.43
- 52 Week High
- LRE $2.49
- GOVX $11.18
- Technical
- Relative Strength Index (RSI)
- LRE 54.60
- GOVX 29.07
- Support Level
- LRE $1.64
- GOVX $0.85
- Resistance Level
- LRE $2.11
- GOVX $0.98
- Average True Range (ATR)
- LRE 0.14
- GOVX 0.15
- MACD
- LRE -0.01
- GOVX -0.04
- Stochastic Oscillator
- LRE 24.49
- GOVX 5.54
About LRE Lead Real Estate Co. Ltd
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment building units to individual customers in Japan and Dallas, Texas. Predominantly, its revenue is generated from developing and selling single-family homes and condominiums. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.